Lag3: From Bench to Bedside.
Journal
Cancer treatment and research
ISSN: 0927-3042
Titre abrégé: Cancer Treat Res
Pays: United States
ID NLM: 8008541
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
18
5
2022
Statut:
ppublish
Résumé
The introduction of immune checkpoint inhibitors represented a breakthrough treatment for metastatic melanoma, but the effect of these agents is not limited to a single cancer type. Promising results have been reported in various solid tumors, for example, lung cancer. The success of these drugs depends on the activation of tumor-infiltrating lymphocytes and primary and acquired resistance have been reported alongside a high rate of immune-related adverse events when agents targeting different immune checkpoints are given in combination. Numerous other targets have been investigated to overcome the resistance, improve the activity, and reduce the toxicity of checkpoint inhibitor therapy. Among these, the most promising is Lymphocyte-activation gene 3 (LAG-3), a transmembrane protein involved in cytokine release and inhibitory signaling in T cells. Preclinical data showed that LAG-3 is a negative regulator of both CD4
Identifiants
pubmed: 35551660
doi: 10.1007/978-3-030-96376-7_6
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
185-199Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Restifo NP, Smyth MJ, Snyder A (2016) Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer 16(2):121–126
pubmed: 26822578
pmcid: 6330026
doi: 10.1038/nrc.2016.2
Saleh R, Elkord E (2020) Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression. Semin Cancer Biol 65:13–27
pubmed: 31362073
doi: 10.1016/j.semcancer.2019.07.017
Lythgoe MP, Liu DSK, Annels NE, Krell J, Frampton AE (2021) Gene of the month: lymphocyte-activation gene 3 (LAG-3). J Clin Pathol 74(9):543–547
pubmed: 34183437
doi: 10.1136/jclinpath-2021-207517
He Y, Rivard CJ, Rozeboom L, Yu H, Ellison K, Kowalewski A et al (2016) Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci 107(9):1193–1197
pubmed: 27297395
pmcid: 5021038
doi: 10.1111/cas.12986
Anderson AC, Joller N, Kuchroo VK (2016) Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44(5):989–1004
pubmed: 27192565
pmcid: 4942846
doi: 10.1016/j.immuni.2016.05.001
Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J et al (2019) Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell 176(1–2):334–47.e12
pubmed: 30580966
doi: 10.1016/j.cell.2018.11.010
Long L, Zhang X, Chen F, Pan Q, Phiphatwatchara P, Zeng Y et al (2018) The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer 9(5–6):176–189
pubmed: 30603054
pmcid: 6305110
doi: 10.18632/genesandcancer.180
Saleh R, Elkord E (2019) Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Lett 457:168–179
pubmed: 31078738
doi: 10.1016/j.canlet.2019.05.003
Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P et al (2014) VISTA regulates the development of protective antitumor immunity. Cancer Res 74(7):1933–1944
pubmed: 24691994
doi: 10.1158/0008-5472.CAN-13-1506
Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F et al (2010) LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 184(11):6545–6551
pubmed: 20421648
doi: 10.4049/jimmunol.0903879
Workman CJ, Vignali DA (2003) The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol 33(4):970–979
pubmed: 12672063
doi: 10.1002/eji.200323382
Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A et al (2007) LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 117(11):3383–3392
pubmed: 17932562
pmcid: 2000807
doi: 10.1172/JCI31184
Deng WW, Mao L, Yu GT, Bu LL, Ma SR, Liu B et al. (2016) LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. Oncoimmunology 5(11):e1239005
Que Y, Fang Z, Guan Y, Xiao W, Xu B, Zhao J et al (2019) LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival. Cancer Biol Med 16(2):331–340
pubmed: 31516753
pmcid: 6713642
doi: 10.20892/j.issn.2095-3941.2018.0306
Maruhashi T, Sugiura D, Okazaki IM, Okazaki T (2020) LAG-3: from molecular functions to clinical applications. J Immunother Cancer 8(2)
Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle KJ et al (2009) Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 182(11):6659–6669
pubmed: 19454660
doi: 10.4049/jimmunol.0804211
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T et al (2010) Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 107(17):7875–7880
pubmed: 20385810
pmcid: 2867907
doi: 10.1073/pnas.1003345107
Wierz M, Pierson S, Guyonnet L, Viry E, Lequeux A, Oudin A et al (2018) Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood 131(14):1617–1621
pubmed: 29439955
pmcid: 5887766
doi: 10.1182/blood-2017-06-792267
Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72(4):917–927
pubmed: 22186141
doi: 10.1158/0008-5472.CAN-11-1620
Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A et al (2013) Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 190(9):4899–4909
pubmed: 23536636
doi: 10.4049/jimmunol.1300271
Kraman M, Faroudi M, Allen NL, Kmiecik K, Gliddon D, Seal C et al (2020) FS118, a bispecific antibody targeting LAG-3 and PD-L1, enhances T-Cell activation resulting in potent antitumor activity. Clin Cancer Res 26(13):3333–3344
pubmed: 32299814
doi: 10.1158/1078-0432.CCR-19-3548
Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K (2017) Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology 6(1):e1249561
Du H, Yi Z, Wang L, Li Z, Niu B, Ren G (2020) The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy. Int Immunopharmacol 78:106113
Everett KL, Kraman M, Wollerton FPG, Zimarino C, Kmiecik K, Gaspar M et al (2019) Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics. Methods 154:60–69
pubmed: 30208333
doi: 10.1016/j.ymeth.2018.09.003
Lecocq Q, Keyaerts M, Devoogdt N, Breckpot K (2020) The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: third time's a charm. Int J Mol Sci 22(1)
Yu X, Huang X, Chen X, Liu J, Wu C, Pu Q et al (2019) Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. MAbs 11(6):1139–1148
pubmed: 31242068
pmcid: 6748621
doi: 10.1080/19420862.2019.1629239
Burova E, Hermann A, Dai J, Ullman E, Halasz G, Potocky T et al (2019) Preclinical development of the anti-LAG-3 antibody REGN3767: characterization and activity in combination with the anti-PD-1 antibody cemiplimab in human PD-1xLAG-3-knockin mice. Mol Cancer Ther 18(11):2051–2062
pubmed: 31395688
doi: 10.1158/1535-7163.MCT-18-1376
Avice MN, Sarfati M, Triebel F, Delespesse G, Demeure CE (1999) Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. J Immunol 162(5):2748–2753
pubmed: 10072520
Buisson S, Triebel F (2003) MHC class II engagement by its ligand LAG-3 (CD223) leads to a distinct pattern of chemokine and chemokine receptor expression by human dendritic cells. Vaccine 21(9–10):862–868
pubmed: 12547595
doi: 10.1016/S0264-410X(02)00533-9
Dirix L, Triebel F (2019) AIPAC: a phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer. Future Oncol 15(17):1963–1973
pubmed: 30977393
doi: 10.2217/fon-2018-0807
Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F et al (2010) First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 8:71
pubmed: 20653948
pmcid: 2920252
doi: 10.1186/1479-5876-8-71
Legat A, Maby-El Hajjami H, Baumgaertner P, Cagnon L, Abed Maillard S, Geldhof C et al (2016) Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients-report of a phase I/IIa clinical trial. Clin Cancer Res 22(6):1330–1340
pubmed: 26500235
doi: 10.1158/1078-0432.CCR-15-1212
Lipson EJ (ed) Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224–047). JCO
Flaherty KT, Hennig M, Lee SJ, Ascierto PA, Dummer R, Eggermont AM et al (2014) Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol 15(3):297–304
pubmed: 24485879
pmcid: 4443445
doi: 10.1016/S1470-2045(14)70007-5
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381(16):1535–1546
pubmed: 31562797
doi: 10.1056/NEJMoa1910836
Romano E, Michielin O, Voelter V, Laurent J, Bichat H, Stravodimou A et al (2014) MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med 12:97
pubmed: 24726012
pmcid: 4021605
doi: 10.1186/1479-5876-12-97
Wildiers (2021) Abstract PD14–08: primary efficacy results from AIPAC: a double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) versus weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients
Yap T (ed) (2020) A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy. BMJ
Saleh RR, Peinado P, Fuentes-Antras J, Perez-Segura P, Pandiella A, Amir E et al (2019) Prognostic value of lymphocyte-activation gene 3 (LAG3) in cancer: a meta-analysis. Front Oncol 9:1040
pubmed: 31681578
pmcid: 6803551
doi: 10.3389/fonc.2019.01040
Fang J, Chen F, Liu D, Gu F, Chen Z, Wang Y (2020) Prognostic value of immune checkpoint molecules in breast cancer. Biosci Rep 40(7)
Al-Badran SS, Grant L, Campo MV, Inthagard J, Pennel K, Quinn J et al (2021) Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer. J Pathol Clin Res. 7(2):121–134
pubmed: 33338327
doi: 10.1002/cjp2.193
Lee SJ, Byeon SJ, Lee J, Park SH, Park JO, Park YS et al (2019) LAG3 in solid tumors as a potential novel immunotherapy target. J Immunother 42(8):279–283
pubmed: 31219974
doi: 10.1097/CJI.0000000000000283
Wu S, Shi X, Wang J, Wang X, Liu Y, Luo Y et al. (2021) Triple-negative breast cancer: intact mismatch repair and partial co-expression of PD-L1 and LAG-3. Front Immunol 12:561793
Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A et al (2018) CD103(+) Tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment. Clin Cancer Res 24(13):3036–3045
pubmed: 29599411
doi: 10.1158/1078-0432.CCR-17-2257
Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC et al (2017) Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170(6):1120–33.e17
pubmed: 28803728
pmcid: 5591072
doi: 10.1016/j.cell.2017.07.024
Richards CH, Roxburgh CS, Powell AG, Foulis AK, Horgan PG, McMillan DC (2014) The clinical utility of the local inflammatory response in colorectal cancer. Eur J Cancer 50(2):309–319
pubmed: 24103145
doi: 10.1016/j.ejca.2013.09.008
Zeng H, Zhou Q, Wang Z, Zhang H, Liu Z, Huang Q et al. (2020) Stromal LAG-3(+) cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture. J Immunother Cancer 8(1)
Kates M, Nirschl TR, Baras AS, Sopko NA, Hahn NM, Su X et al (2021) Combined next-generation sequencing and flow cytometry analysis for an anti-PD-L1 partial responder over time: an exploration of mechanisms of PD-L1 activity and resistance in bladder cancer. Eur Urol Oncol 4(1):117–120
pubmed: 31411999
doi: 10.1016/j.euo.2019.01.017
Hald SM, Rakaee M, Martinez I, Richardsen E, Al-Saad S, Paulsen EE et al. (2018) LAG-3 in non-small-cell lung cancer: expression in primary tumors and metastatic lymph nodes is associated with improved survival. Clin Lung Cancer 19(3):249–59 e2
Jung EH, Jang HR, Kim SH, Suh KJ, Kim YJ, Lee JH et al (2021) Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thorac Cancer 12(5):619–630
pubmed: 33458968
pmcid: 7919166
doi: 10.1111/1759-7714.13834
Klumper N, Ralser DJ, Bawden EG, Landsberg J, Zarbl R, Kristiansen G et al. (2020) LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. J Immunother Cancer 8(1)
Dancsok AR, Setsu N, Gao D, Blay JY, Thomas D, Maki RG et al (2019) Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. Mod Pathol 32(12):1772–1785
pubmed: 31263176
doi: 10.1038/s41379-019-0312-y
Mochizuki K, Kawana S, Yamada S, Muramatsu M, Sano H, Kobayashi S et al (2019) Various checkpoint molecules, and tumor-infiltrating lymphocytes in common pediatric solid tumors: possibilities for novel immunotherapy. Pediatr Hematol Oncol 36(1):17–27
pubmed: 30870043
doi: 10.1080/08880018.2019.1578843
Rotte A, Jin JY, Lemaire V (2018) Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol 29(1):71–83
pubmed: 29069302
doi: 10.1093/annonc/mdx686
Saleh R, Sasidharan Nair V, Toor SM, Taha RZ, Murshed K, Al-Dhaheri M et al. (2020) Differential gene expression of tumor-infiltrating CD8(+) T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis. J Immunother Cancer 8(2)
Saleh R, Toor SM, Khalaf S, Elkord E (2019) Breast cancer cells and PD-1/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoints in CD4(+) T Cells. Vaccines (Basel) 7(4)
Saleh R, Toor SM, Elkord E (2020) Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential. Expert Opin Ther Targets 24(12):1251–1262
pubmed: 33103506
doi: 10.1080/14728222.2020.1841750
The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function (2018) Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies. https://usptoreport/patent/grant/10.844.119